))
Is Onshoring Biomanufacturing Really Happening?
Manage episode 500960465 series 3428201
A tartalmat a Kymanox biztosítja. Az összes podcast-tartalmat, beleértve az epizódokat, grafikákat és podcast-leírásokat, közvetlenül a Kymanox vagy a podcast platform partnere tölti fel és biztosítja. Ha úgy gondolja, hogy valaki az Ön engedélye nélkül használja fel a szerzői joggal védett művét, kövesse az itt leírt folyamatot https://hu.player.fm/legal.
As pharmaceutical companies grow, they face critical choices: Where should you manufacture your product? How do you choose the right CDMO? What risks come with global supply chains?
In this episode of Life Science Solutions, host Chris Adkins sits down with Roger Lias, PhD a 35-year veteran of the biologics manufacturing industry, to dig into the realities of onshoring in pharma and the evolving CDMO landscape.
Roger walks through geopolitics and the BIOSECURE Act to the practical hurdles of talent shortages and infrastructure buildouts. Roger outlines what sponsor companies need to consider when choosing a domestic or international partner, from experience working in APAC.
Topics include:
- Why “onshoring” may be more political theater than operational shift
- The labor and infrastructure gap in U.S. biologics manufacturing
- How CDMO specialization is reshaping the global pharma supply chain
From navigating regulatory risks to building smart tech transfer plans, this episode gives growing pharma teams the tools to make better decisions.
📍 Recorded at Kymanox HQ in Research Triangle Park, North Carolina.
#Biomanufacturing #CDMO #Onshoring #LifeSciences #Biologics #PharmaManufacturing
36 epizódok
Megosztás
